Cadila Health to market new diabetes drug in India

MUMBAI (Reuters) – Drugmaker Cadila Healthcare Ltd received regulatory approval to market a new diabetes drug in India that it developed and is aiming for more than $1 billion in sales globally, the company said on Wednesday. Cadila, India’s sixth-largest drugmaker by sales, spent $250 million developing Lipaglyn, a new chemical entity or new discovery, and aims to spend another $150 million to $200 million to launch the drug outside India, the company’s chairman, Pankaj Patel, said. …